hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06272279, orgStudyIdInfo id: HS23666(B2020:015), briefTitle: Neuromodulation With Spinal Stimulation Methods, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-03-01, primaryCompletionDateStruct date: 2024-12-31, completionDateStruct date: 2025-02-01, studyFirstPostDateStruct date: 2024-02-22, lastUpdatePostDateStruct date: 2024-02-22, sponsorCollaboratorsModule leadSponsor name: University of Manitoba, class: OTHER, descriptionModule briefSummary: This is a pilot research study to test the protocols needed for transcutaneous spinal electrical stimulation in persons living with spinal cord injury (SCI). Up to 24 participants will be enrolled. A variety of stimulation parameters and outcome measures will be assessed., conditionsModule conditions: Spinal Cord Injuries, conditions: Spinal Cord Injury at C5-C7 Level, conditions: Paraplegia, Spinal, conditions: Paraplegia, Incomplete, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: CROSSOVER, interventionModelDescription: Semi-blinded, randomized block entry design, crossover intervention study., primaryPurpose: BASIC_SCIENCE, maskingInfo masking: DOUBLE, maskingDescription: The participant will be connected to the stimulation device(s) but will not know if it has been turned on during each trial. In addition, the person analyzing the outcome data will not be aware of the stimulation status of the participant., whoMasked: PARTICIPANT, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 24, type: ESTIMATED, armsInterventionsModule interventions name: spinal stimulation-DCS, interventions name: spinal stimulation-sham DCS, interventions name: spinal stimulation-EPS, interventions name: sham spinal stimulation-EPS, outcomesModule primaryOutcomes measure: Motor response, primaryOutcomes measure: Motor evoked potentials, secondaryOutcomes measure: Blood pressure, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 65 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: University of Manitoba, status: ENROLLING_BY_INVITATION, city: Winnipeg, state: Manitoba, zip: R3E 0J9, country: Canada, geoPoint lat: 49.8844, lon: -97.14704, locations facility: University of Manitoba, status: RECRUITING, city: Winnipeg, state: Manitoba, zip: R3E 0J9, country: Canada, contacts name: Katinka Stecina, Ph.D., role: CONTACT, phone: 2047893761, email: Katinka.Stecina@umanitoba.ca, contacts name: Kristine Cowley, Ph.D., role: CONTACT, phone: 2047893305, email: Kristine.Cowley@umanitoba.ca, geoPoint lat: 49.8844, lon: -97.14704, hasResults: False
protocolSection identificationModule nctId: NCT06272253, orgStudyIdInfo id: UNAIR-MP-INAKTIF-R-010, briefTitle: UNAIR Inactivated COVID-19 Vaccine INAVAC as Heterologue Booster (Immunobridging Study) in Adolescent Subjects, statusModule overallStatus: ACTIVE_NOT_RECRUITING, startDateStruct date: 2023-09-19, primaryCompletionDateStruct date: 2024-03-19, completionDateStruct date: 2024-07-19, studyFirstPostDateStruct date: 2024-02-22, lastUpdatePostDateStruct date: 2024-02-22, sponsorCollaboratorsModule leadSponsor name: Dr. Soetomo General Hospital, class: OTHER_GOV, collaborators name: Indonesia-MoH, collaborators name: Universitas Airlangga, collaborators name: PT Biotis Pharmaceuticals, Indonesia, descriptionModule briefSummary: This is an open label trial. There will only be 1 group in the study. All subjects will receive INAVAC vaccine and be followed for 6 months.The vaccine will be administered intramuscularly. This study will be started after the interim analysis of the phase III INAVAC trial in adolescent. This study will have two interim and one full analysis reports., conditionsModule conditions: COVID-19 Pandemic, conditions: COVID-19 Vaccines, designModule studyType: INTERVENTIONAL, phases: EARLY_PHASE1, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: PREVENTION, maskingInfo masking: NONE, enrollmentInfo count: 250, type: ACTUAL, armsInterventionsModule interventions name: INAVAC (Vaksin Merah Putih - UA- SARS CoV-2 (Vero Cell Inactivated) 5 μg, outcomesModule primaryOutcomes measure: Humoral Immune Response (Neutralizing antibody), secondaryOutcomes measure: Incidence of Adverse Events, secondaryOutcomes measure: Humoral Immune Response - The neutralizing antibody, secondaryOutcomes measure: Humoral Immune Response-IgG SARS-CoV-2 neutralizing titer by CLIA, otherOutcomes measure: Exploratory Endpoints-Whole Genome Sequencing, eligibilityModule sex: ALL, minimumAge: 12 Years, maximumAge: 17 Years, stdAges: CHILD, contactsLocationsModule locations facility: Dr. Soetomo General Hospital, city: Surabaya, state: Jawa Timur, zip: 67161, country: Indonesia, geoPoint lat: -7.24917, lon: 112.75083, hasResults: False
protocolSection identificationModule nctId: NCT06272240, orgStudyIdInfo id: 17380, briefTitle: Tumor Microenvironment in Ovarian Cancer, acronym: MICO, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-01-02, primaryCompletionDateStruct date: 2024-07, completionDateStruct date: 2027-01, studyFirstPostDateStruct date: 2024-02-22, lastUpdatePostDateStruct date: 2024-02-22, sponsorCollaboratorsModule leadSponsor name: University of Udine, class: OTHER, descriptionModule briefSummary: A detailed understanding of molecular mechanism of cancer genesis is fundamental to develop innovative and personalized therapies. The new frontier in biomedical research is represented by organoids, a three-dimensional cell culture system obtained from a tissue fragment that accurately reproduces the essential properties of the original tissue in vitro, which could provide a valuable model for explanation of ovarian cancers pathogenesis and will allow to predict the response to a specific therapy. With this research project, we expect to generate ovarian cancer organoids to characterize in vitro interactions and molecular pathway among tumor cells, immune cells, and resident microbiota (intratumoral bacteria and/or microbial-derived molecules)., conditionsModule conditions: Ovarian Cancer Stage III, conditions: Ovarian Cancer Stage IV, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_ONLY, timePerspective: PROSPECTIVE, enrollmentInfo count: 50, type: ESTIMATED, armsInterventionsModule interventions name: Ovarian Cancer Organoids, outcomesModule primaryOutcomes measure: • Composition of the tumor microenvironment (including the immune system and intratumoral microbiota). • Generate organoids, eligibilityModule sex: FEMALE, minimumAge: 18 Years, maximumAge: 80 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Università degli Studi di Udine, status: RECRUITING, city: Udine, state: UD, zip: 33100, country: Italy, geoPoint lat: 46.0693, lon: 13.23715, hasResults: False
protocolSection identificationModule nctId: NCT06272227, orgStudyIdInfo id: 4-2023-0986, briefTitle: Effect of Alfacalcidol on Muscle Function in Osteoporosis Patients, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-02-13, primaryCompletionDateStruct date: 2025-09-01, completionDateStruct date: 2025-09-01, studyFirstPostDateStruct date: 2024-02-22, lastUpdatePostDateStruct date: 2024-02-22, sponsorCollaboratorsModule leadSponsor name: Yonsei University, class: OTHER, descriptionModule briefSummary: This study aims to investigate the potential improvement in muscle function, compared to the placebo group, through the concurrent administration of denosumab and alfacalcidol over a one-year period in postmenopausal women with functional sarcopenia and osteoporosis aged 65 and older. The study is planned as a double-blinded randomized controlled trial, intending to recruit a total of 340 participants. Primary outcome is the improvement in SPPB score of 0.5 or more compared to the control group., conditionsModule conditions: Sarcopenia, designModule studyType: INTERVENTIONAL, phases: PHASE4, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: QUADRUPLE, whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 340, type: ESTIMATED, armsInterventionsModule interventions name: alfacalcidol, interventions name: placebo, interventions name: Denosumab, outcomesModule primaryOutcomes measure: Improvement in SPPB score of 0.5 or more compared to the control group, eligibilityModule sex: FEMALE, minimumAge: 65 Years, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Division of Endocrinology, Department of internal Medicine, Yonsei University College of Medicine, Severance Hospital, city: Seoul, zip: 03722, country: Korea, Republic of, geoPoint lat: 37.566, lon: 126.9784, hasResults: False
protocolSection identificationModule nctId: NCT06272201, orgStudyIdInfo id: 50620 TPR, briefTitle: Incisionless Suture Plications in a POSE2.0 Interventional Randomized Obesity Study, acronym: INSPIRO, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-11, primaryCompletionDateStruct date: 2026-08, completionDateStruct date: 2026-08, studyFirstPostDateStruct date: 2024-02-22, lastUpdatePostDateStruct date: 2024-02-22, sponsorCollaboratorsModule leadSponsor name: USGI Medical, class: INDUSTRY, descriptionModule briefSummary: This is a multi-center, open-label, 2-group randomized pivotal study evaluating a minimally invasive weight loss procedure. The intent is to evaluate the safety and effectiveness of POSE2.0 (sutures placed in the mid + distal body without placement in the fundus), with a moderate intensity diet and exercise program, as compared to diet and exercise alone. The procedure will be performed using the g-Cath EZ Delivery Catheter with Snowshoe Suture Anchors (AKA g-Cath or g-Cath EZ) and associated devices (g-Prox EZ, g-Lix and Transport), known collectively as the Incisionless Operating Platform (IOP)., conditionsModule conditions: Obesity, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 186, type: ESTIMATED, armsInterventionsModule interventions name: POSE2.0 procedure with g-Cath EZ Delivery Catheter with Snowshoe Suture Anchors, outcomesModule primaryOutcomes measure: Percentage of total body weight loss (%TBWL) following randomization, primaryOutcomes measure: Responder rate of at least 50% in the POSE2.0 treatment group, primaryOutcomes measure: Safety- Incidence of device and procedure related adverse events through 12 months, eligibilityModule sex: ALL, minimumAge: 22 Years, maximumAge: 65 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06272175, orgStudyIdInfo id: 10102023, briefTitle: Immediate Effects of Open and Closed Kinetic Chain Exercises on Upper Extremity in Stroke Patients., statusModule overallStatus: RECRUITING, startDateStruct date: 2024-03-04, primaryCompletionDateStruct date: 2024-09-30, completionDateStruct date: 2024-12-30, studyFirstPostDateStruct date: 2024-02-22, lastUpdatePostDateStruct date: 2024-03-07, sponsorCollaboratorsModule leadSponsor name: Istinye University, class: OTHER, descriptionModule briefSummary: Stroke is a sudden disruption of blood flow to the brain, resulting in physical and mental disabilities. It's a global health issue affecting millions each year, often leading to paralysis, altered muscle tone, and loss of motor control and balance. This study aims to examine the immediate effects of open and closed kinetic chain activites on upper extremity spasticity and motor dexterity in hemiplegic patients. This study will be conducted simultaneously at İstinye University Hospital Medical Park Gaziosmanpaşa and İstinye University Physiotherapy and Rehabilitation Application and Research Center (İSÜFİZYOTEM). 50 stroke patients will be included in the study, and all participants will be asked to sign an informed consent form. At the beginning of the session, all participants will be evaluated for their socio-demographic characteristics by a questionnaire created by the researchers, muscle viscoelastic properties by MyotonPRO, upper extremity muscle tone by Modified Ashworth Scale, upper extremity motor dexterity by Box and Block Test, and upper extremity joint range of motion by goniometer and by a phone application named as PhysioMaster. After the assessment, participants will be randomly assigned to two groups: open kinetic chain activity group and closed kinetic chain activity group. After performing the exercises, all evaluations will be conducted again. Thus, the aim is to understand the immediate effects of two different group exercises on the evaluated parameters., conditionsModule conditions: Stroke, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: DOUBLE, whoMasked: PARTICIPANT, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 50, type: ESTIMATED, armsInterventionsModule interventions name: Open Kinetic Chain Activity, interventions name: Closed Kinetic Chain Activity, outcomesModule primaryOutcomes measure: MyotonPRO digital palpation device, primaryOutcomes measure: Box and Block Test, secondaryOutcomes measure: Modified Ashworth Scale, secondaryOutcomes measure: Goniometer, secondaryOutcomes measure: PhysioMaster, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 70 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Istinye University Hospital Medical Park Gaziosmanpasa, status: RECRUITING, city: Istanbul, country: Turkey, contacts name: Mehmet Salih Baran, Assist. Prof., role: CONTACT, geoPoint lat: 41.01384, lon: 28.94966, hasResults: False
protocolSection identificationModule nctId: NCT06272149, orgStudyIdInfo id: VGN-R08b-001, briefTitle: An Exploratory Clinical Trial of VGN-R08b in Patients With Type II Gaucher Disease, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-03-01, primaryCompletionDateStruct date: 2025-01-15, completionDateStruct date: 2029-02-28, studyFirstPostDateStruct date: 2024-02-22, lastUpdatePostDateStruct date: 2024-02-22, sponsorCollaboratorsModule leadSponsor name: Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, class: OTHER, collaborators name: Shanghai Vitalgen BioPharma Co., Ltd., descriptionModule briefSummary: This exploratory trial is to prove the tolerability and safety of VGN-R08b to treat infants with type II Gaucher disease., conditionsModule conditions: Type II Gaucher Disease, designModule studyType: INTERVENTIONAL, phases: EARLY_PHASE1, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 6, type: ESTIMATED, armsInterventionsModule interventions name: VGN-R08b, outcomesModule primaryOutcomes measure: Number of Adverse Events (AEs), Serious Adverse Events (SAEs), secondaryOutcomes measure: Long-term safety follow-up, secondaryOutcomes measure: Survival ratio at age of 24 months, secondaryOutcomes measure: Changes in the activity of glucose cerebroside lipase (GCase), secondaryOutcomes measure: Changes in the activity of glucose cerebroside (GC) levels, secondaryOutcomes measure: Changes in the activity of glucose sphingosine (Lyso GL1) levels in peripheral blood and CSF after medication, secondaryOutcomes measure: Immunogenicity, secondaryOutcomes measure: Changes in the genomic level of VGN-R08b vector in peripheral blood after medication, eligibilityModule sex: ALL, minimumAge: 0 Months, maximumAge: 24 Months, stdAges: CHILD, contactsLocationsModule locations facility: Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, status: RECRUITING, city: Shanghai, state: Shanghai, zip: 200097, country: China, contacts name: Zhang Huiwen, Dr., role: CONTACT, phone: 18117165075, email: zhanghuiwen@xinhuamed.com.cn, geoPoint lat: 31.22222, lon: 121.45806, hasResults: False
protocolSection identificationModule nctId: NCT06272136, orgStudyIdInfo id: SPN-007, briefTitle: Spiden Non-invasive Continuous Glucose Monitor "Clinical Demo" (niCGM), statusModule overallStatus: RECRUITING, startDateStruct date: 2024-02-23, primaryCompletionDateStruct date: 2024-11-30, completionDateStruct date: 2024-12-31, studyFirstPostDateStruct date: 2024-02-22, lastUpdatePostDateStruct date: 2024-02-28, sponsorCollaboratorsModule leadSponsor name: Spiden AG, class: INDUSTRY, collaborators name: Profil Institut für Stoffwechselforschung GmbH, descriptionModule briefSummary: This is a single-centre, multiple sequential-cohort, open study., conditionsModule conditions: Type 1 Diabetes, conditions: Type2diabetes, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: OTHER, maskingInfo masking: NONE, enrollmentInfo count: 40, type: ESTIMATED, armsInterventionsModule interventions name: Clinical Demo 2.0, outcomesModule primaryOutcomes measure: Glucose changes will be measured noninvasively and transcutaneously in dynamic states of glycaemia, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 65 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Profil for Stoffwechselforschung GmbH, status: RECRUITING, city: Neuss, state: Nordrhein-Westfallen, zip: 41460, country: Germany, contacts name: Marc Stoffel, MD, role: CONTACT, phone: 0049213140180, geoPoint lat: 51.19807, lon: 6.68504, hasResults: False
protocolSection identificationModule nctId: NCT06272123, orgStudyIdInfo id: 20D.776, briefTitle: Endotypic Stability in CRS, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-01-01, primaryCompletionDateStruct date: 2026-01-31, completionDateStruct date: 2026-01-31, studyFirstPostDateStruct date: 2024-02-22, lastUpdatePostDateStruct date: 2024-02-22, sponsorCollaboratorsModule leadSponsor name: Thomas Jefferson University, class: OTHER, collaborators name: GlaxoSmithKline, descriptionModule briefSummary: A Case control study with 150 cases and 50 controls will be conducted. Immunologic (cytokines measurements in nasal secretions and sinonasal tissues), histopathologic (tissue eosinophilia) and clinical parameters (Lund-Mackay and Lund-Kennedy score, lung function tests), surveys (SNOT- 22, SF-36 quality of life survey) will be compared between different groups of patients, conditionsModule conditions: Chronic Sinusitis, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_CONTROL, timePerspective: OTHER, enrollmentInfo count: 200, type: ESTIMATED, armsInterventionsModule interventions name: no intervention, outcomesModule primaryOutcomes measure: Endotypic markers, secondaryOutcomes measure: SF-36, secondaryOutcomes measure: SNOT-22, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 100 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Thomas Jefferson University Department of Otolaryngology, status: RECRUITING, city: Philadelphia, state: Pennsylvania, zip: 19107, country: United States, contacts name: Elizabeth Kangas, RN, BSN, role: CONTACT, phone: 215-955-6784, email: elizabeth.kangas@jefferson.edu, geoPoint lat: 39.95233, lon: -75.16379, hasResults: False
protocolSection identificationModule nctId: NCT06272097, orgStudyIdInfo id: 201328, briefTitle: Postoperative Difficult-to-Heal Wounds of Clinical Trial Registration, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-01, primaryCompletionDateStruct date: 2024-10-01, completionDateStruct date: 2024-11-15, studyFirstPostDateStruct date: 2024-02-22, lastUpdatePostDateStruct date: 2024-02-22, sponsorCollaboratorsModule leadSponsor name: Danni Feng, class: OTHER, descriptionModule briefSummary: This study aims to investigate the effectiveness of an optimized care management protocol for refractory postoperative wounds based on the TIME CDST tool. Through a randomized controlled trial approach, the investigators will conduct a rigorous comparative analysis of the experimental group and the control group. The intervention group will receive an intervention plan based on the TIME CDST tool led by wound specialist nurses at each dressing change, while the control group receive a routine wound care program of wound cleaning and dressing changes at each dressing change. The main research objective is to evaluate the superiority of the experimental group compared with the control group in terms of wound healing time, healing quality, and patient satisfaction. Through the implementation of this study, the investigators expect to provide an effective optimization scheme for the management of refractory postoperative wounds in clinical practice, thereby improving patient outcomes and quality of life., conditionsModule conditions: Wound Heal, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: DOUBLE, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 144, type: ESTIMATED, armsInterventionsModule interventions name: Intervention program based on TIME-CDST tool led by wound specialist nurses, interventions name: A routine wound care program, outcomesModule primaryOutcomes measure: Wound healing time, secondaryOutcomes measure: The wound healing rate, secondaryOutcomes measure: The rate of wound area reduction, secondaryOutcomes measure: The Pressure Ulcer Scale for Healing (PUSH), secondaryOutcomes measure: The positive rate of bacterial culture, secondaryOutcomes measure: The pain intensity, secondaryOutcomes measure: Patient comfort score, secondaryOutcomes measure: Patient satisfaction score, secondaryOutcomes measure: The levels of albumin, secondaryOutcomes measure: The number of dressing changes, secondaryOutcomes measure: Medical costs, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06272084, orgStudyIdInfo id: CRRT-TPE-01-DE, briefTitle: Analysis of TPE Treatments With multiFiltratePRO, acronym: TPEopt, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05, primaryCompletionDateStruct date: 2024-09, completionDateStruct date: 2024-12, studyFirstPostDateStruct date: 2024-02-22, lastUpdatePostDateStruct date: 2024-04-19, sponsorCollaboratorsModule leadSponsor name: Fresenius Medical Care Deutschland GmbH, class: INDUSTRY, collaborators name: X-act Cologne Clinical Research GmbH, descriptionModule briefSummary: Analysis of therapeutic plasma exchange (TPE) treatments to assess the performance of the TPE mode of multiFiltratePRO based on the successful exchange of plasma from whole blood. The multiFiltratePRO is a device for extracorporeal blood purification treatments., conditionsModule conditions: Autoimmune Diseases, designModule studyType: OBSERVATIONAL, designInfo observationalModel: OTHER, timePerspective: RETROSPECTIVE, enrollmentInfo count: 60, type: ESTIMATED, armsInterventionsModule interventions name: Therapeutic Plasma Exchange (TPE) option of multiFiltratePRO, outcomesModule primaryOutcomes measure: Total amount of exchange plasma (prescribed vs achieved exchange volume), eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Klinikum Aschaffenburg-Alzenau, city: Aschaffenburg, state: Bavaria, zip: 63739, country: Germany, contacts name: Stefan Büttner, Dr. med., role: CONTACT, email: Stefan.buettner@klinikum-ab-alz.de, geoPoint lat: 49.97704, lon: 9.15214, hasResults: False